Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Equity Ratio (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Equity Ratio for 11 consecutive years, with 0.84 as the latest value for Q4 2025.

  • Quarterly Equity Ratio changed N/A to 0.84 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.84 through Dec 2025, changed N/A year-over-year, with the annual reading at 0.84 for FY2025, N/A changed from the prior year.
  • Equity Ratio for Q4 2025 was 0.84 at Crescent Biopharma, roughly flat from 0.84 in the prior quarter.
  • The five-year high for Equity Ratio was 0.91 in Q1 2021, with the low at 5.03 in Q1 2025.
  • Average Equity Ratio over 5 years is 0.5, with a median of 0.86 recorded in 2022.
  • Peak annual rise in Equity Ratio hit 1117.1% in 2025, while the deepest fall reached 695.51% in 2025.
  • Over 5 years, Equity Ratio stood at 0.86 in 2021, then fell by 4.2% to 0.83 in 2022, then grew by 2.31% to 0.85 in 2023, then crashed by 109.78% to 0.08 in 2024, then skyrocketed by 1118.63% to 0.84 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.84, 0.84, and 0.88 for Q4 2025, Q3 2025, and Q2 2025 respectively.